“Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma” has been added to your cart. View cart

Article: Carfilzomib-dexamethasone: a new ‘best in class’ in multiple myeloma

€3.03

SKU: product-article-18801 Category: General

Description
Reviews (0)

Description

Carfilzomib-dexamethasone: a new ‘best in class’ in multiple myeloma

Reviews

There are no reviews yet.

Be the first to review “Article: Carfilzomib-dexamethasone: a new ‘best in class’ in multiple myeloma”

You must be logged in to post a review.

Top

Article: Carfilzomib-dexamethasone: a new ‘best in class’ in multiple myeloma

Description

Reviews

Related products

Article: Highlights in breast cancer

Article: Highlights in respiratory oncology

Article: Highlights in urologic cancer

Article: Highlights in urologic cancer